|
Market Closed -
Other stock markets
|
After hours 03:09:12 pm | |||
| 225.10 EUR | +0.90% |
|
225.95 | +0.38% |
| 08:08am | MoonLake's psoriatic arthritis drug meets key goals in late-stage trial | RE |
| Aug. 05 | UCB Publishes Results Of Post Hoc Data Analysis Of Fintepla In Patients With Lennox-Gastaut Syndrome | CI |
| Market Cap | 42.54B 49.14B 39.76B 36.34B 68.48B 4,686B 69.55B 466B 183B 2,344B 184B 180B 7,808B | P/E 2026 * |
22.7x | P/E 2027 * | 18.4x |
|---|---|---|---|---|---|
| Enterprise Value | 42.71B 49.34B 39.92B 36.49B 68.76B 4,705B 69.83B 468B 184B 2,354B 185B 181B 7,840B | EV / Sales 2026 * |
4.94x | EV / Sales 2027 * | 4.19x |
| Free-Float |
61.59% | Yield 2026 * |
0.65% | Yield 2027 * | 0.67% |
Last Transcript: UCB
| 1 day | +0.90% | ||
| 1 week | +1.67% | ||
| Current month | +0.99% | ||
| 1 month | -5.06% | ||
| 3 months | -4.54% | ||
| 6 months | -15.06% | ||
| Current year | -5.66% |
| 1 week | 221.6 |  | 232.9 |
| 1 month | 214 | | 251.5 |
| Current year | 214 | | 289.5 |
| 1 year | 184.75 | | 289.5 |
| 3 years | 65.4 | | 289.5 |
| 5 years | 65.4 | | 289.5 |
| 10 years | 54.84 | | 289.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 2014-12-31 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 2020-06-30 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 2024-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 2011-12-31 | |
| Director/Board Member | 67 | 2014-12-31 | |
| Director/Board Member | 56 | 2014-04-23 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 1/15/26 | Fiscal year | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 1/15/26 | Fiscal year | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 1/15/26 | Buy | Director | 500 | 0.0003% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.90% | +1.67% | +20.63% | +176.54% | 49.18B | |
| +3.17% | +5.24% | +46.35% | +0.75% | 78.32B | |
| +0.84% | +5.66% | -0.15% | +27.88% | 51.1B | |
| +1.72% | +9.27% | -48.46% | -48.80% | 44.71B | |
| -0.38% | +2.61% | +61.78% | -23.04% | 30.72B | |
| +1.03% | +2.91% | +53.91% | +86.05% | 24.44B | |
| +0.19% | +7.93% | +133.65% | -40.66% | 23.62B | |
| +2.58% | +12.23% | +6.63% | +202.17% | 21.05B | |
| -0.62% | +3.30% | +64.98% | +114.68% | 16.61B | |
| +0.75% | +6.09% | +75.85% | +161.90% | 16.51B | |
| Average | +1.03% | +3.91% | +41.52% | +65.75% | 35.63B | |
| Weighted average by Cap. | +1.27% | +3.91% | +31.76% | +48.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.65B 9.99B 8.09B 7.39B 13.93B 953B 14.14B 94.81B 37.2B 477B 37.52B 36.7B 1,588B | 9.7B 11.2B 9.07B 8.29B 15.61B 1,069B 15.86B 106B 41.72B 535B 42.07B 41.15B 1,780B |
| Net income | 1.87B 2.16B 1.75B 1.6B 3.01B 206B 3.06B 20.53B 8.05B 103B 8.12B 7.95B 344B | 2.34B 2.71B 2.19B 2B 3.77B 258B 3.83B 25.67B 10.07B 129B 10.16B 9.94B 430B |
| Net Debt | 174M 202M 163M 149M 281M 19.22B 285M 1.91B 750M 9.62B 757M 740M 32.03B | -1.94B -2.24B -1.81B -1.66B -3.12B -214B -3.17B -21.26B -8.34B -107B -8.41B -8.23B -356B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-10 | €225.10 | +0.90% | 195,294 |
| 26-08-07 | €223.10 | -0.84% | 194,018 |
| 26-08-06 | €225.00 | -1.83% | 193,762 |
| 26-08-05 | €229.20 | +2.64% | 264,506 |
| 26-08-04 | €223.30 | +0.86% | 258,008 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- UCB Stock
Select your edition
All financial news and data tailored to specific country editions
